Evidence map›Paper›PMID 35282434›Full record

SynthesisFrontiers in endocrinology2022

Hashimoto's Thyroiditis: A "Double-Edged Sword" in Thyroid Carcinoma.

Jiangyue Xu, Ke Ding, Lan Mu, Jiangsheng Huang, Fei Ye, Yu Peng, Can Guo, Chutong Ren

Open access · goldAbstract readMeta-Analysis
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Frontiers in endocrinology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 69 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
69citing papers in PubMed, 5 pooled it
11.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

69 citing papers in PubMed, 5 syntheses or guidelines pooled it, 88 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article

9 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Jiangyue XuDepartment of General Surgery Thyroid Specialty, The Second Xiangya Hospital of Central South University, Changsha, China.
Ke DingDepartment of Urology, Xiangya Hospital, Central South University, Changsha, China.
Lan MuDepartment of General Surgery Thyroid Specialty, The Second Xiangya Hospital of Central South University, Changsha, China.
Jiangsheng HuangDepartment of General Surgery Thyroid Specialty, The Second Xiangya Hospital of Central South University, Changsha, China.
Fei YeDepartment of General Surgery Thyroid Specialty, The Second Xiangya Hospital of Central South University, Changsha, China.
Yu PengDepartment of General Surgery Thyroid Specialty, The Second Xiangya Hospital of Central South University, Changsha, China.
Can GuoDepartment of General Surgery Thyroid Specialty, The Second Xiangya Hospital of Central South University, Changsha, China.
Chutong RenDepartment of General Surgery Thyroid Specialty, The Second Xiangya Hospital of Central South University, Changsha, China.
Central South University · CNSecond Xiangya Hospital of Central South University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The prevalence of thyroid carcinoma (TC) and Hashimoto's thyroiditis (HT) has been increasing dramatically over the past decades. We investigated the relationship between HT and TC. Methods: We followed the Meta-analysis of Observational Studies in Epidemiology (MOOSE) guidelines for carrying out and reporting this meta-analysis. The literature from January 1, 2010 to December 31, 2020, regardless of region and publication type, was searched comprehensively in PubMed, Embase, Web of Science, and Cochrane Library databases. After careful selection and data extraction, the pooled odds ratio of various clinical characteristics in 39 studies were calculated. Publication bias was analyzed using funnel plots. Results: Meta-analysis of 39 original research articles showed HT to be a risk factor of TC (pooled odds ratio = 1.71; 95% confidence interval, 1.57-1.80; Conclusions: HT is a "double-edged sword" in TC patients. HT increases the risk of TC and PTC but is a protective factor against PTC progression.

Indexed as

CarcinomaHashimoto DiseaseThyroid NeoplasmsHumansMutationObservational Studies as TopicThyroid Cancer, PapillaryBRAFV600E mutationHashimoto’s thyroiditis (HT)meta-analysispapillary thyroid carcinomathyroid carcinoma (TC)

Identifiers

PMID35282434
PMCPMC8907134
OpenAlexW4213420668

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.